In one of the latest studies, researchers from Iran analyzed the impact of a proprietary formula containing plant-based CBD and THC in a 10:1 ratio, which was created by Yas Daru, a pharmaceutical firm in Tehran. It was given to 50 diabetic patients diagnosed with type 2 diabetes sublingually to help keep glucose as well as cholesterol levels in check. The study participants administered the sublingual spray twice a day for 8 weeks.
Trulieve becomes the first U.S. cannabis company to trade on the NYSE on June 10.…
From robot canopy scanners to algorithmic breeders to AI-powered dispensary counters, artificial intelligence is remaking…
The latest version of this story comes from Virginia Commonwealth University, where researcher Emanuele Alves…
But there's more to this image than nostalgia and comedy. What you're looking at in…
The league pulled marijuana off its banned list in the new players’ agreement. In the…
In New South Wales, Australia, patients can legally use medical cannabis with a prescription. So…